Mandate

Vinge advises Axcel in connection with the launch of Accru Partners, a new group within accounting, tax, audit and advisory services

October 04, 2024

Vinge has advised the Nordic private equity firm Axcel in connection with its establishment of Accru Partners, a new group of 22 independent firms in Sweden within accounting, tax, audit and other advisory services.

All firms in the group are entrepreneur-led, local businesses with expertise in accounting, tax, audit and advisory services. In total, the new group employs around 500 people with over 30 offices in Sweden.

Vinge’s team consisted of Christina Kokko, Desirée Hagenfeldt, Egil Svensson, Robin Fagerström, Michella Lina Said, Madelene Andersson, Niklas Suni and Alexander Rüdén (M&A), Simon Söderholm, Narin Melazade, Jonatan Stentorp and Melinda Oldenburg (Employment), Kamyar Najmi, Ida Redander and Sofia Haggren (Banking and Finance), Mario Saad, Jolene Reimerson and Carl Lexenberg (Commercial Agreements), Mathilda Persson and Elis Allmark (IT), Rebecka Målquist (Intellectual Property), Nicklas Thorgerzon (GDPR), Agnes Pigg and Hanna Kövamees (Real Property), Kristoffer Sällfors (Public Procurement), David Olander (EU and Competition), Jonna Bondemark and David Gavatin (Regulatory), Mia Falk, Gulestan Ali and Maja Höglund (Compliance) samt Jessica Öijer (Transaction Support Coordinator).


Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026